相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Re-visiting Hypersensitivity Reactions to Taxanes: A Comprehensive Review
Matthieu Picard et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2015)
Phase 2 Trial of Paclitaxel Polyglumex with Capecitabine for Metastatic Breast Cancer
Donald W. Northfelt et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2014)
Induction cetuximab, paclitaxel, and carboplatin followed by chemoradiation with cetuximab, paclitaxel, and carboplatin for stage III/IV head and neck squamous cancer: a phase II ECOG-ACRIN trial (E2303)
H. J. Wanebo et al.
ANNALS OF ONCOLOGY (2014)
The impact of taxanes on the management of genitourinary cancers
Arjun V. Balar
ANTI-CANCER DRUGS (2014)
Taxanes in the management of metastatic castration-resistant prostate cancer: Efficacy and management of toxicity
Fabio A. Schutz et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2014)
A Phase 2 Trial of Radiation Therapy With Concurrent Paclitaxel Chemotherapy After Surgery in Patients With High-Risk Endometrial Cancer: A Korean Gynecologic Oncologic Group Study
Hanbyoul Cho et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
Simultaneous quantification of MTC-220 and its metabolites in beagle dog plasma by liquid chromatography-tandem mass spectrometry
Xin Liu et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2014)
Formulating the magic bullet: barriers to clinical translation of nanoparticle cancer gene therapy
William P. D. Hendricks et al.
NANOMEDICINE (2014)
nab-Paclitaxel: Novel Clinical and Experimental Evidence in Pancreatic Cancer
A. Neesse et al.
ZEITSCHRIFT FUR GASTROENTEROLOGIE (2014)
Paclitaxel Formulations: Challenges and Novel Delivery Options
Chetan Nehate et al.
CURRENT DRUG DELIVERY (2014)
Management of Hypersensitivity Reactions to Carboplatin and Paclitaxel in an Outpatient Oncology Infusion Center: A 5-Year Review
Aleena Banerji et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2014)
Engineering the Assemblies of Biomaterial Nanocarriers for Delivery of Multiple Theranostic Agents with Enhanced Antitumor Efficacy
Hai Wang et al.
ADVANCED MATERIALS (2013)
Enhanced drug-loading and therapeutic efficacy of hydrotropic oligomer-conjugated glycol chitosan nanoparticles for tumor-targeted paclitaxel delivery
Heebeom Koo et al.
JOURNAL OF CONTROLLED RELEASE (2013)
Clinical efficacy and safety of a water-soluble micellar paclitaxel (Paccal Vet) in canine mastocytomas
P. Rivera et al.
JOURNAL OF SMALL ANIMAL PRACTICE (2013)
A dose-finding study with a novel water-soluble formulation of paclitaxel for the treatment of malignant high-grade solid tumours in dogs
H. von Euler et al.
VETERINARY AND COMPARATIVE ONCOLOGY (2013)
A Randomized Trial Investigating the Efficacy and Safety of Water Soluble Micellar Paclitaxel (Paccal Vet) for Treatment of Nonresectable Grade 2 or 3 Mast Cell Tumors in Dogs
D. M. Vail et al.
JOURNAL OF VETERINARY INTERNAL MEDICINE (2012)
Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced Solid Tumors
Razelle Kurzrock et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Efficacy of taxanes as adjuvant treatment of breast cancer: a review and meta-analysis of randomised clinical trials
Jordi Gines et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2011)
Phase I dose escalation safety study of nanoparticulate paclitaxel (CTI 52010) in normal dogs
Sandra M. Axiak et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2011)
Preparation and the in-vivo evaluation of paclitaxel liposomes for lung targeting delivery in dogs
Ling Zhao et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2011)
Randomized Trial of Paclitaxel Versus Pegylated Liposomal Doxorubicin for Advanced Human Immunodeficiency Virus-Associated Kaposi Sarcoma Evidence of Symptom Palliation From Chemotherapy
Mary Cianfrocca et al.
CANCER (2010)
Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma
Jade Homsi et al.
MELANOMA RESEARCH (2010)
Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, TaxoprexinA®, in resistant solid tumor malignancies
Paula M. Fracasso et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Peripheral neuropathy induced by paclitaxel: Recent insights and future perspectives
CD Scripture et al.
CURRENT NEUROPHARMACOLOGY (2006)
Disposition of paclitaxel (Taxol®) and its metabolites in patients with advanced breast cancer (ABC) when combined with trastuzumab (Hercpetin®)
A Furtlehner et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2005)
Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophor (Taxol)
A Sparreboom et al.
CLINICAL CANCER RESEARCH (2005)
A structure - Activity study of taxol, taxotere, and derivatives using the electronic indices methodology (EIM)
SF Braga et al.
JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES (2003)
A novel controlled release formulation for the anticancer drug paclitaxel (Taxol®):: PLGA nanoparticles containing vitamin E TPGS
L Mu et al.
JOURNAL OF CONTROLLED RELEASE (2003)
分享论文
